DMMDA

DMMDA
Clinical data
Other names	2,5-Dimethoxy-3,4-methylenedioxyamphetamine; DMMDA; DMMDA-1
Routes of; administration	Oral
Drug class	Serotonergic psychedelic; Hallucinogen
ATC code	None;
Legal status
Legal status	CA: Schedule I; UK: Class A;
Pharmacokinetic data
Duration of action	6–8 hours
Identifiers
	IUPAC name 1-(4,7-Dimethoxy-1,3-benzodioxol-5-yl)propan-2-amine;
CAS Number	15183-13-8 ;
PubChem CID	44349928;
ChemSpider	21106291 ;
UNII	Y6T4R5Z3VU;
ChEMBL	ChEMBL126311 ;
CompTox Dashboard (EPA)	DTXSID40658367 ;
Chemical and physical data
Formula	C12H17NO4
Molar mass	239.271 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(N)Cc1cc(OC)c2OCOc2c1OC;
	InChI InChI=1S/C12H17NO4/c1-7(13)4-8-5-9(14-2)11-12(10(8)15-3)17-6-16-11/h5,7H,4,6,13H2,1-3H3 ; Key:GRGRGLVMGTVCNZ-UHFFFAOYSA-N ;
	(verify)

2,5-Dimethoxy-3,4-methylenedioxyamphetamine (DMMDA or DMMDA-1) is a lesser-known psychedelic drug of the amphetamine and MDxx families related to MMDA. It was first synthesized by Alexander Shulgin in the 1960s and was described in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).